Save information for later
Sign Up

Learn About Angiosarcoma of the Liver

View Main Condition: Angiosarcoma

What is the definition of Angiosarcoma of the Liver?
A malignant vascular neoplasm arising from the liver.
What are the alternative names for Angiosarcoma of the Liver?
  • Angiosarcoma of the liver
Who are the top Angiosarcoma of the Liver Local Doctors?
Elite in Angiosarcoma of the Liver
Elite in Angiosarcoma of the Liver
Kantonsspital St. Gallen, 
Sankt Gallen, SG, CH 

David Semela practices in Sankt Gallen, Switzerland. Mr. Semela is rated as an Elite expert by MediFind in the treatment of Angiosarcoma of the Liver. His top areas of expertise are Angiosarcoma of the Liver, Angiosarcoma, Hepatitis C, Hepatitis, and Liver Transplant.

Elite in Angiosarcoma of the Liver
Hepatology
Elite in Angiosarcoma of the Liver
Hepatology

University Of Louisville Physicians Inc

401 E Chestnut St, Suite 310, 
Louisville, KY 
Languages Spoken:
English

Matthew Cave is a Hepatologist in Louisville, Kentucky. Dr. Cave is rated as an Elite provider by MediFind in the treatment of Angiosarcoma of the Liver. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Angiosarcoma of the Liver, Alcoholic Cirrhosis, Hepatitis, and Endoscopy.

 
 
 
 
Learn about our expert tiers
Learn More
Elliot K. Fishman
Distinguished in Angiosarcoma of the Liver
Distinguished in Angiosarcoma of the Liver

The Johns Hopkins Hospital

1800 Orleans Street, 
Baltimore, MD 
Languages Spoken:
English

Dr. Elliot K. Fishman is a Professor in the Johns Hopkins Medicine Department Radiology and Radiological Science, Department of Oncology and Department of Surgery. He serves as a member of the Johns Hopkins Kimmel Cancer Center. His clinical and research interests focus on medical imaging with specific emphasis on three-dimensional (3D) imaging and computed tomography (CT). Dr. Fishman received his B.S. in 1973 and M.D. in 1977 from the University of Maryland. After a residency at Sinai Hospital in Baltimore, he completed a fellowship in CT at Johns Hopkins in 1980 and joined the Johns Hopkins faculty in 1981 as an Assistant Professor. In 1986, he became Associate Professor and, in 1991, Professor of Radiology and Oncology. He is a leader in the development of 3D imaging and rendering, including its impacts on and uses in patient care and management. He was involved from the beginning in the development of 3D imaging through his work with Pixar, which was a spin-off from LucasFilms in San Rafael, California. Over the last 25 years, Dr. Fishman continued to help develop 3D imaging and has been a leader in the development of interactive 3D rendering. His team is consistently at the forefront of research and development of new visualization and post-processing techniques and technologies. Dr. Fishman's extensive body of work in CT has resulted in over 1,000 peer-reviewed publications, and he is the author or co-author of 10 textbooks. He is the recipient of three prestigious Aunt Minnie Awards, honoring his outstanding contributions as both an educator and researcher. In 2007, he was named by Medical Imaging Magazine as the Top Radiologist in the Nation. He is a member of editorial boards for more than 35 journals, an active member of several professional radiology associations and is a past-president of the Society of Body CT/MR. Dr. Fishman is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma of the Liver. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Ductal Adenocarcinoma, Cavernous Lymphangioma, Pancreaticoduodenectomy, and Pancreatectomy.

What are the latest Angiosarcoma of the Liver Clinical Trials?
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

Summary: The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational stud...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1, Open-Label, Dose-Escalation and Expansion Study of AGX101, a TM4SF1 Directed Antibody Drug Conjugate in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors

Summary: AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progressio...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center